Oculis Holding (OCS)

• Market cap: $1.01B
• 1 day: -4.03%
• 5 days: -9.61%
• 1 month: 9.67%
• 3 months: 9.3%
• 6 months: 10.8%
• Year to date: 13.88%
• 1 year: 12.22%
• 5 years: 77.04%
• 10 years: 77.04%
• Sector: Healthcare
• Industry: Biotechnology

About: Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.

Employees: 49